BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Real-time Borsa Italiana 03:58:58 2024-07-02 EDT | ||
| 9.47 EUR | +2.71% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 9.47 | +2.71% |
| 24-07-01 | 9.22 | +7.21% |
| 24-06-28 | 8.6 | -2.27% |
| 24-06-27 | 8.8 | +8.37% |
| 24-06-26 | 8.12 | -1.93% |
Real-time Borsa Italiana
Last update July 02, 2024 at 03:58 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| S36740 | |
| ISIN | DE000SY136T3 |
| Date issued | 2024-06-25 |
| Strike | 819.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.51 € |
|---|---|
| Lowest since issue | 7.13 € |
| Spread | 0.28 € |
| Spread % | 2.94% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.97%
- Stock Market
- Certificates
- S36740 Certificat
